Korro Bio (KRRO) Competitors

Korro Bio (NASDAQ:KRRO) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.

Which has more risk & volatility, KRRO or TRVI?

Korro Bio has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Does the media prefer KRRO or TRVI?

In the previous week, Trevi Therapeutics had 7 more articles in the media than Korro Bio. MarketBeat recorded 11 mentions for Trevi Therapeutics and 4 mentions for Korro Bio. Korro Bio's average media sentiment score of 1.35 beat Trevi Therapeutics' score of 0.62 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is KRRO or TRVI more profitable?

Korro Bio's return on equity of -50.25% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-50.25%	-38.48%
Trevi Therapeutics	N/A	-63.31%	-57.06%

Do institutionals & insiders have more ownership in KRRO or TRVI?

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 5.4% of Korro Bio shares are owned by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts prefer KRRO or TRVI?

Korro Bio presently has a consensus price target of $136.33, indicating a potential upside of 917.41%. Trevi Therapeutics has a consensus price target of $17.56, indicating a potential upside of 183.27%. Given Korro Bio's higher possible upside, analysts clearly believe Korro Bio is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Trevi Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.30

Which has preferable valuation and earnings, KRRO or TRVI?

Trevi Therapeutics has lower revenue, but higher earnings than Korro Bio. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$2.27M	55.40	-$81.17M	-$9.39	-1.43
Trevi Therapeutics	N/A	N/A	-$29.07M	-$0.47	-13.19

Does the MarketBeat Community prefer KRRO or TRVI?

Trevi Therapeutics received 80 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 67.95% of users gave Trevi Therapeutics an outperform vote.

Company	Underperform	Outperform
Korro Bio	Outperform Votes 26 100.00%	Underperform Votes No Votes
Trevi Therapeutics	Outperform Votes 106 67.95%	Underperform Votes 50 32.05%

Summary

Trevi Therapeutics beats Korro Bio on 9 of the 17 factors compared between the two stocks.